The ECYT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ECYT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ECYT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View ECYT Detailed Price Forecast - CNN Money||View ECYT Detailed Summary - Google Finance|
|View ECYT Detailed Summary - Yahoo! Finance||View ECYT Stock Research & Analysis - Zacks.com|
|View ECYT Trends & Analysis - Trade-Ideas||View ECYT Major Holders - Barrons|
|View ECYT Call Transcripts - NASDAQ||View ECYT Breaking News & Analysis - Seeking Alpha|
|View ECYT Annual Report - CompanySpotlight.com||View ECYT OTC Short Report - OTCShortReport.com|
|View ECYT Fundamentals - TradeKing||View ECYT SEC Filings - Bar Chart|
|View Historical Prices for ECYT - The WSJ||View Performance/Total Return for ECYT - Morningstar|
|View the Analyst Estimates for ECYT - MarketWatch||View the Earnings History for ECYT - CNBC|
|View the ECYT Earnings - StockMarketWatch||View ECYT Buy or Sell Recommendations - MacroAxis|
|View the ECYT Bullish Patterns - American Bulls||View ECYT Short Pain Metrics - ShortPainBot.com|
|View ECYT Stock Mentions - StockTwits||View ECYT Stock Mentions - PennyStockTweets|
|View ECYT Stock Mentions - Twitter||View ECYT Investment Forum News - Investor Hub|
|View ECYT Stock Mentions - Yahoo! Message Board||View ECYT Stock Mentions - Seeking Alpha|
|View Insider Transactions for ECYT - SECform4.com||View Insider Transactions for ECYT - Insider Cow|
|View ECYT Major Holdings Summary - CNBC||View Insider Disclosure for ECYT - OTC Markets|
|View Insider Transactions for ECYT - Yahoo! Finance||View Institutional Holdings for ECYT - NASDAQ|
|View ECYT Stock Insight & Charts - FinViz.com||View ECYT Investment Charts - StockCharts.com|
|View ECYT Stock Overview & Charts - BarChart||View ECYT User Generated Charts - Trading View|
Winners and Losers From the Biggest Cancer Meeting of the Year (So Far)
Posted on Friday May 18, 2018
The meeting hasn't even started, and stocks are already moving.
Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC
Posted on Friday May 18, 2018
LONDON, UK / ACCESSWIRE / May 18, 2018 / If you want access to our free research report on Insmed Inc. (NASDAQ: INSM), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=INSM as the Company's latest news hit the wire. On May 16, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ALIS (Amikacin Liposome Inhalation Suspension) for treatment of adult patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Should You Be Concerned With Endocyte Inc’s (NASDAQ:ECYT) -15.38% Earnings Drop?
Posted on Thursday May 17, 2018
For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Endocyte Inc’s (NASDAQ:ECYT) track record on a high level, to giveRead More...
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
Posted on Wednesday May 16, 2018
Endocyte, Inc. (ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that a poster with data from the Peter MacCallum Cancer Centre will be presented on Endocyte’s lead investigational therapy at the 2018 ASCO Annual Meeting on Saturday, June 2, 2018. Updated data from the phase 2 study of 177Lu-PSMA-617 as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC), including data from an additional 20 patient expansion cohort, will be highlighted by the poster. “We are very pleased that we continue to see high rates of PSA response, even in heavily pre-treated patients,” said Mike Sherman, president and CEO of Endocyte.